Role of endogenous glucagon‐like peptide‐1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes-Reference-Cited by-同舟云学术

Role of endogenous glucagon‐like peptide‐1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes

Published:2019-12-05 Issue:3 Volume:22 Page:383-392
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Xie Cong¹,Wang Xuyi¹²,Jones Karen L.¹³^ORCID,Horowitz Michael¹³,Sun Zilin²,Little Tanya J.¹,Rayner Christopher K.¹⁴^ORCID,Wu Tongzhi¹²³^ORCID

Affiliation:

1. Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good HealthUniversity of Adelaide Adelaide South Australia Australia

2. Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of MedicineSoutheast University Nanjing China

3. Endocrine and Metabolic UnitRoyal Adelaide Hospital Adelaide South Australia Australia

4. Department of Gastroenterology and HepatologyRoyal Adelaide Hospital Adelaide South Australia Australia

Funder

Novartis

Royal Adelaide Hospital

National Health and Medical Research Council

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13906

Reference48 articles.

1. Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*

2. Comparative effects of proximal and distal small intestinal glucose exposure on glycemia, incretin hormone secretion, and the incretin effect in health and type 2 diabetes;Zhang X;Diabetes Care,2019

3. Small Intestinal Glucose Exposure Determines the Magnitude of the Incretin Effect in Health and Type 2 Diabetes

4. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

5. Four Weeks of Near-Normalization of Blood Glucose has no Effect on Postprandial GLP-1 and GIP Secretion, but Augments Pancreatic B-Cell Responsiveness to a Meal in patients with Type 2 Diabetes

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study;Diabetologia;2024-04-01

2. Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon‐like peptide 1;Clinical and Experimental Pharmacology and Physiology;2024-03-25

3. Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial;Diabetes, Obesity and Metabolism;2024-01-16

4. Determinants of blood glucose concentrations following a high carbohydrate meal in type 2 diabetes: A multiple linear regression analysis;Diabetes Research and Clinical Practice;2023-04

5. Disparities in the Glycemic and Incretin Responses to Intraduodenal Glucose Infusion Between Healthy Young Men and Women;The Journal of Clinical Endocrinology & Metabolism;2023-03-29